<DOC>
	<DOCNO>NCT00363025</DOCNO>
	<brief_summary>In ALFA-9803 trial AML patient age 65 year , randomly compare idarubicin daunorubicin throughout study ( first randomization ) two different post-remission strategy ( second randomization ) : one single intensive consolidation course similar induction versus six ambulatory cycle one dose idarubicin/daunorubicin ( day 1 ) 2x60 mg/m2/d cytarabine SC ( day 1 5 ) deliver out-patients monthly basis . Primary endpoint 2-year overall survival ( OS ) . Study hypotheses equivalence idarubicin/daunorubicin comparison 15 % difference 2-year OS post-remission therapy comparison .</brief_summary>
	<brief_title>A Randomized Study Post-Remission Therapy Elderly Patients With Acute Myelogenous Leukemia .</brief_title>
	<detailed_description>Patients randomize baseline ( first R1 randomization ) receive either daunorubicin ( DNR ) idarubicin ( IDA ) anthracycline induction post-remission therapy . This first randomization stratify center AML type ( de novo versus post-MDS AML ) . Induction chemotherapy consist 4+7 course either DNR daily dosage 45 mg/m2 IDA daily dosage 9 mg/m2 four day ( day 1 day 4 ) combination 200 mg/m2 cytarabine per day continuous IV infusion seven day ( day 1 7 ) . Lenograstim granulocyte colony-stimulating factor ( G-CSF ) administer patient day 9 myeloid recovery ( 3 consecutive day PMN 1.0 G/L ) IV infusion daily dosage 263 microg/day maximum 28 day . A blood marrow aspiration smear examination perform day 21 . A salvage course chemotherapy may offer patient persistent leukemia ( define ) , present acquire contra-indication intensive chemotherapy ( baseline criterion ) . Salvage consist six 1-hour IV bolus intermediate-dose cytarabine ( 500 mg/m2/12h day 1 3 ) combine mitoxantrone ( MTZ ) daily dosage 12 mg/m2 two day ( day 3 4 ) . G-CSF administration stop salvage onset restart day 5 salvage course myeloid recovery maximum 28 day . Patients reach complete remission ( CR ) induction induction follow salvage eligible second R2 randomization mild versus intensive post-remission therapy , present acquire contra-indication intensive chemotherapy ( baseline criterion ) . This second randomization stratify center , AML group ( de novo versus post-MDS AML ) , first randomization group . Mild post-remission therapy administer out-patients consist six 1+5 monthly course either 45 mg/m2 DNR 9 mg/m2 IDA one day ( day 1 ) combination 60 mg/m2/12h cytarabine SC infusion five day ( day 1 5 ) . No G-CSF support give six course . Intensive post-remission therapy require another hospitalization repetition first 4+7 induction administer dos follow G-CSF administration well .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Male female age 65 year . Patient previously untreated AML except M3 FAB classification . Patient previously untreated transformed refractory anemia excess blast ( RAEBt ) . Patients AML secondary previously untreated myelodysplastic syndrome ( MDS ) , document , eligible , well RAEBt evolve previous know MDS . Patients Performance Status &lt; 3 . Patient give his/her write informed consent . Patients AML3 FAB classification . Patients blast crisis previously know myeloproliferative syndrome . Patients AML secondary previous treatment cytotoxic chemotherapy radiotherapy ( therapyrelated AML ) . Patients another concommitant neoplasia . Patients leukemic central nervous system involvement . Patients Grade &gt; 2 uncontrolled infection . Patients Grade &gt; 2 visceral contraindication treatment induction chemotherapy ( except leukemiarelated ) . Bilirubin &gt; 2 time normal range laboratory . Serum creatinine &gt; 2 time normal range laboratory . Patients cardiac contraindication treatment anthracyclines .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>Older patient</keyword>
	<keyword>Patient age 65 year</keyword>
</DOC>